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Background
Dupilumab (DPL) is a fully human IL-4Ra monoclonal
antibody that potently inhibits both IL-4 and IL-13
signaling, drivers of T-helper 2 (Th2) mediated inflam-
mation. In early clinical trials, DPL has recently been
evaluated in proof-of-concept studies in asthma and
atopic dermatitis (AD).
Methods
The clinical trial design and results in adult patients were
previously reported for asthma (NEJM 2013;368:2455)
and AD (JID 2013;133:S177-S178). In the asthma study,
inhaled glucocorticoids and long-acting beta-agonist
were withdrawn after week 4 [W4] of 12 weeks of qw
DPL [300 mg] or placebo [PBO]. Asthma exacerbation
occurrence was the primary endpoint. Fractional exhaled
nitric oxide (FeNO) and blood eotaxin-3, TARC and IgE
were measured as pharmacodynamic markers. Two AD
studies in adults with moderate-to-severe AD evaluated
DPL (75, 150, 300 mg) or PBO qw for 4 weeks on itch
(5D pruritus questionnaire), Eczema Area and Severity
Index (EASI), TARC and total IgE.
Results
DPL was generally well tolerated in asthma and AD. The
most frequent adverse events associated with DPL treat-
ment were nasopharyngitis and headache. Key efficacy
endpoints were achieved in both asthma and AD. In
asthma, DPL significantly suppressed (mean % change
from baseline) TARC (W4: -29 DPL vs. +7 PBO; W12: -26
DPL vs. +8 PBO), eotaxin-3 (W4: -37 DPL vs. +3 PBO;
W12: -46 DPL vs. +5 PBO), total IgE (W4: -10 DPL vs.
+14 PBO; W12: -37 DPL vs. +6 PBO) and FeNO (mean %
change from baseline W4: -40 DPL vs. -5 PBO; W12: -29
DPL vs. +35 PBO). Improvement in FEV1 and the reduc-
tion in FeNO were significantly correlated. In AD, 300 mg
DPL markedly suppressed TARC (mean -66% DPL vs. -8%
PBO) at W4. IgE gradually declined (300 mg, mean -31%
DPL vs. +9% for PBO at W12, 9 wks after last dose).
TARC levels significantly correlated with the 5D pruritus
score at baseline and W4.
Conclusions
The suppression by DPL of Th2 biomarkers in both
asthma and AD concur with improvement in key clini-
cal endpoints. Declines in TARC, as well as eotaxin-3 in
asthma, suggest that DPL suppresses Th2-mediated
secretion of chemotaxins that perpetuate inflammation.
Declines in IgE indicate that DPL suppresses Th2-
mediated polarization of Ig-producing cells. A reduction
in FeNO demonstrated a reduction in airway inflamma-
tion, which correlated with improved lung function
(FEV1). The correlation of pruritus with TARC suggests
Th2 inflammation may, in part, mediate itch in AD.
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